Regeneron reports preliminary Q4 U.S. EYLEA HD sales of $123M; IPR&D charge of $30M

REGENERON PHARMACEUTICALS, INC.

2023-FY EPS reported $34.77 revenue$13,117,200,000

Preliminary Q4 2023 U.S. net product sales: EYLEA HD $123M, EYLEA $1.34B, combined $1.46B.
Acquired IPR&D charge of $30M pre-tax from Intellia collaboration extension, reducing GAAP and non-GAAP EPS by ~$0.21.
Dupixent global net sales through 9M 2023: ~$8.4B, up 34% YoY; pivotal COPD data supports 2024 launch potential.
EYLEA HD FDA-approved August 2023 for wAMD, DME, DR; ~2/3 of eligible lives covered, permanent J-code expected April 1, 2024.
Oncology pipeline: BLAs submitted for odronextamab (B-NHL) and linvoseltamab (MM); potential for up to three FDA approvals by end of 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

REGENERON PHARMACEUTICALS, INC. reported fourth quarter 2023 results: EPS $0.21.

Period: fourth quarter 2023
EPS: $0.21
Result: preliminary results

Exact text from the filing

the Company’s preliminary (unaudited) fourth quarter 2023 U.S. net product sales of EYLEA ® HD (aflibercept) Injection 8 mg of approximately $123 million and the Company’s preliminary (unaudited) fourth quarter 2023 U.S. net product sales of EYLEA ® (aflibercept) Injection of approximately $1.34 billion

View on SEC.gov

Browse all earnings releases →

REGENERON PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-002037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.